Previous Article | Next Article ![]()
Infection and Immunity, May 2005, p. 2690-2697, Vol. 73, No. 5
0019-9567/05/$08.00+0 doi:10.1128/IAI.73.5.2690-2697.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Department of Bacteriology, University of WisconsinMadison, 1925 Willow Drive, Madison, Wisconsin 53706
Received 4 August 2004/ Returned for modification 29 September 2004/ Accepted 4 January 2005
|
|
|---|
|
|
|---|
-helices that lend rigidity to the folded structure (29); the molecules are displayed as homodimers oriented with the hydrophilic N-terminal portion of the protein toward the extracellular space and with glycosylphosphatidylinositol anchors tethering the C terminus to the plasma membrane (9, 11, 29). Together, these characteristics permit a highly ordered packing of VSG molecules into the surface coat structure. Despite extensive primary sequence variation among different VSGs, secondary and tertiary structural features of these molecules are highly conserved (11, 12, 29, 31), perhaps ensuring that all VSG molecules are packaged similarly into a surface coat structure during the process of antigenic variation. Stringent allelic exclusion ensures that only 1 of approximately 1,000 different VSG genes in the genome is transcribed at any given time from a chromosome telomere (reviewed in references 10, 13, and 17). Thus, normally only one species of VSG molecule is present within the trypanosome surface coat, resulting in the homogeneous display of identical surface epitopes in exposed N-terminal regions of the molecules; this exposed multiepitope array is capable of activating B cells in a T-independent manner, and early recognition by the immune system and clearance of trypanosomes from the bloodstream are largely mediated by a T-independent, VSG-specific immunoglobulin M (IgM) response (27, 32, 33, 36). In other microbial systems, a correlation has been established between T-independent activation of B cells and the degree of epitope repetitiveness, surface rigidity, spatial arrangement, and orientation of epitopes to achieve full B-cell activation (3, 40-42, 47). Thus, the VSG surface coat structure of trypanosomes both theoretically and functionally meets these criteria for T-independent B-cell activation.
However, during the process of antigenic variation, one homogeneous surface coat is replaced over a period of time by a new homogeneous coat. Transcription of a new VSG gene plus translation and trafficking of new mature VSG homodimers to the cell surface, coupled with residual mRNA and protein stability of the old VSG coat, result in transient expression of both the former and the nascent VSG species on the cell surface for up to 48 h during the process of antigenic variation (4, 18, 19, 38). This "mosaic" VSG surface coat has not previously been examined for its ability to prime the host immune system to the newly arising VSG species. The kinetics of antibody responses to VSG surface coats displayed by trypanosomes at the first peak of parasitemia and the kinetics of antibody responses to different VSG coats displayed by variant antigenic types (VATs) in subsequent waves of parasitemia are similar, suggesting that B cells are not primed to new VSG molecules expressed earlier in mosaic surface coats of preceding double expressers.
It is not known at present whether B cells are able to recognize and become activated by a mosaic display of old and new VSGs that are present on the cell surface during the process of antigenic variation. We hypothesized that a mosaic arrangement of surface epitopes may effectively prevent emerging VSG species from directly activating B cells until the trypanosome surface coat reaches homogeneity (e.g., when the previous surface coat has been completely replaced by the new one). In the present study, therefore, we tested this hypothesis by creating genetically modified trypanosomes that constitutively express both the endogenous LouTat 1 VSG gene from its native chromosome telomeric expression site and an exogenous 117 VSG gene transcribed from a ribosomal DNA locus. We have determined that VSG double-expresser parasites displaying a mosaic coat containing two different VSG species do not activate early T-independent B-cell responses to produce VSG-specific antibodies.
|
|
|---|
Trypanosomes. Frozen stabilates of Trypanosoma brucei rhodesiense clone LouTat 1 and Trypanosoma brucei brucei MiTat 1.4 were grown in Swiss mice prior to establishment of experimental infections. Swiss mice were immunosuppressed by cyclophosphamide treatment (300 mg/kg body weight; Sigma, St. Louis, MO) prior to intraperitoneal infection with LouTat 1 trypanosomes. This treatment suppresses B-cell responses to the VSG molecule and prevents immune selection for minor VATs (39); expression of the LouTat 1 VSG surface coat and expression of the LouTat 1 VSG gene from its telomeric expression site are relatively stable in the absence of immune selection (26). Parasites were isolated from the blood when parasitemia reached 109 trypanosomes/ml blood, as previously described (43). Briefly, animals were exsanguinated from the retrobulbar sinus into a heparinized tube. Blood was diluted with phosphate-buffered saline (PBS) supplemented with 1% glucose, pH 8 (PBSG), and passed over a Selectacel DEAE type 40 (Polysciences, Warrington, PA) column equilibrated with PBSG. By this technique, cellular blood components are bound to the column matrix while trypanosomes pass through (25). Trypanosomes were collected on ice, washed with ice-cold PBSG by centrifugation at 1,000 x g for 10 min at 4°C, and counted in a hemocytometer. As outlined below, LouTat 1 trypanosomes were genetically transformed with vector DNA containing the 117 VSG gene and a neomycin resistance gene (G418-selectable marker) and were subsequently propagated in G418-treated scid mice (50 mg G418/kg body weight given at 0, 24, and 48 h postinfection) prior to experimental infections of C57BL/6 wt and nu/nu mice in the absence of G418 selection.
Antibodies. Antisera against LouTat 1 VSG and 117 VSG were generated in rabbits and mice. LouTat 1 VSG antiserum was affinity purified by positive selection on a LouTat 1 VSG-coupled AminoLink (Pierce Biotechnology, Rockford, IL) column. Bound proteins were eluted in glycine (pH 2.5) and the eluate negatively selected on a 117 VSG column. Likewise, 117 VSG antiserum was positively selected on a 117 VSG column and the eluate negatively selected on a LouTat 1 VSG column. VSG specificity was confirmed by Western blotting, immunoprecipitation, and immunofluorescence (data not shown). Species-specific Alexa 488- and Alexa 633-conjugated secondary antibodies, as well as 4',6'-diamidino-2-phenylindole (DAPI) stain, were purchased from Molecular Probes (Eugene, OR).
Generation of VSG gene double expressers. The pXS5neo117 constitutive bloodstream-stage expression vector was a generous gift from James Bangs (University of Wisconsin, Madison). pXS5neo has been previously described (2) and was provided to us with the 117 VSG gene cloned into the multiple cloning site (Fig. 1). Transformation of bloodstream-stage trypanosomes with linearized pXS5 has been previously described (2). Briefly, 107 LouTat 1 trypanosomes were mixed with 50 µg of linearized pXS5neo117 vector DNA in a final volume of 500 µl Cytomix in a 0.2-mm cuvette and were electroporated (R2, 1.5 kV, no capacitance) in a BTX600 cell manipulator (BTX Inc., San Diego, CA). The following adaptation was made from the published protocol for in vivo drug-selection of transformants, because T. b. rhodesiense LouTat 1 trypanosomes do not grow in vitro. Cells were rested in HMI-9 (23) for 24 h at 37°C, 5% CO2, prior to infection of G418-treated scid mice. A clonal population of successful transformants was derived by infection of G418-treated scid mice with a single parasite. Frozen stabilates were made from the resulting infection and were used for all future studies; expansion of stabilates for all experimental studies was carried out under drug selection in G418-treated scid mice.
![]() View larger version (9K): [in a new window] |
FIG. 1. pXS5 expression vector for ectopic VSG gene expression from the ribosomal locus of trypanosomes. From 5' to 3', the vector contains a nontranscribed targeting sequence from the 3' end of a ribosomal repeat (Ribo 3'); the rRNA promoter (Ribo Prom); the 3' end of the procyclic acidic repetitive protein (PARP) B2 splice acceptor site; the 117 VSG gene inserted into the multiple cloning site; the aldolase intergenic region (Aldo Int), containing a polyadenylation site and a 3' splice acceptor site; the neomycin phosphotransferase gene (neor); and the tubulin ß intergenic region (Tub ß Int), also containing polyadenylation and slice acceptor sites. Linearization of the vector with XhoI targets the construct to replace a ribosomal repeat. Expression of neomycin phosphotransferase results in resistance to the neomycin analog G418 to allow for selection of transformants in vivo or in vitro. Asterisk, splice acceptor site; An, polyadenylation site.
|
RT-PCR analysis of LT1:117 double expressers. Drug-selected transformants were purified from whole blood as described above. Total RNA was isolated according to the manufacturer's instructions for the Ultraspec-II RNA isolation system (Biotecx Laboratories, Houston, TX). RNA was reverse transcribed and amplified using the Access reverse transcription-PCR (RT-PCR) system (Promega, Madison, WI) and gene-specific primers. The following synthetic deoxyoligonucleotides were designed using LaserGene primer analysis software (DNAStar, Inc., Madison, WI) and synthesized by Integrated DNA Technologies (Coralville, IA) (all sequences are 5' to 3'): TLTF sense, ATTACAAAGGGGGAGGTGGAGACT; TLTF antisense, CCGCTTGTTCTGTTCATTCTGCT; LouTat 1 VSG sense (VSG 2383), GGACGCAAGTCTACCTAGCAGC; LouTat 1 VSG antisense (VSG 2382), CTGCAAGTGTCTACCGATGCC; 117 VSG sense (117p3U), TGGAGGCGATCAACGATGCT; 117 VSG antisense (117p3L), TCCGCTTGTTGTCAGTGTCCC.
Immunofluorescent microscopy. Immunostaining and fluorescent microscopy were done by established methods (2). Briefly, fixed and permeabilized T. brucei LouTat 1, MiTat 1.4 (117 VSG), or VSG double-expresser trypanosomes were stained with affinity-purified anti-LouTat VSG or anti-117 VSG antibodies. Specific staining was visualized with appropriate species-specific Alexa 488- and Alexa 633-conjugated secondary reagents. Cells were counterstained with DAPI to visualize nuclear and kinetoplast components for cellular orientation. Stained cells were visualized at x100 on a motorized Zeiss Axioplan IIi equipped with a rear-mounted excitation filter wheel, a triple-pass (DAPI-fluoroscein isothiocyanate-Texas Red) emission cube, and a Zeiss AxioCam black-and-white charge-coupled device camera. Fluorescence images were pseudocolored and merged using OpenLabs 3.0 software (Improvision, Inc., Lexington, MA).
Immunoprecipitation. Radiolabeling of trypanosomes and immunoprecipitation with affinity-purified VSG-specific antibodies were performed as described previously (6, 7). Briefly, LouTat 1 and LT1:117 trypanosomes were radiolabeled with [35S]Met/Cys (Expre35S35S; DuPont, NEN) for 4 h at 37°C; VSG protein sequence information predicted that 23 Met/Cys (14 Met, 14 Cys) residues would be labeled for the 117 protein and that 18 Met/Cys (5 Met, 13 Cys) residues would be labeled for LouTat 1 protein. Cells were separated from medium and lysed in the presence of protease inhibitors. Lysates were incubated with an affinity-purified rabbit anti-LouTat 1 VSG or anti-117 VSG antibody preadsorbed to protein A-Sepharose CL-4B beads (Amersham Pharmacia); the two antibodies precipitated equivalent amounts of VSG from lysates of homotypic antigenic variants (data not shown). Beads were washed and bound proteins separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Bands were detected by autoradiography, and the resulting images were analyzed using GeneTools gel imaging software (Hitachi Genetic Systems; Hitachi Software Engineering Co., Ltd.). To confirm that VSGs in the LT1:117 double expressers were expressed only as homodimers and not as heterodimers, proteins immunoprecipitated with anti-LouTat VSG or anti-117 VSG were transferred to nitrocellulose filters and probed with anti-117 or anti-LouTat 1 VSG, respectively, followed by detection with the appropriate secondary reagents (data not shown).
VSG-specific ELISA and B-cell ELISPOT assays. Enzyme-linked immunosorbent assays (ELISAs) to detect VSG-specific antibodies were performed as described previously (36). Briefly, 4 µg/ml soluble LouTat 1 VSG or 117 VSG in PBS was adsorbed to Immulon 4 ELISA plates (Thermo Lab Systems, Franklin, MA). Plates were incubated overnight at 4°C and washed. Serial dilutions of antisera from nu/nu mice infected with LouTat or LT1:117 trypanosomes for 0 through 5 days were then added to the plates. VSG-specific antibodies were detected with appropriate biotin-conjugated secondary reagents and p-nitrophenyl phosphate as a substrate. The B-cell enzyme-linked immunospot (ELISPOT) assays were done as we have described previously (36). Briefly, 10 µg/ml of the relevant VSG in PBS was bound to wells of Multiscreen-IP 96-well filtration plates (Millipore) at 4°C overnight. Plates were washed and blocked with PBS containing 5% fetal bovine serum; subsequently, 105 splenocytes in 100 µl RPMI with 10% fetal bovine serum were aliquoted into triplicate wells. Cells were cultured for 20 h, and bound cells secreting VSG-specific antibodies were detected with biotinylated anti-mouse IgM (Sigma) following extensive washing. Color was developed with alkaline phosphatase (Vectastain ABC-AP; Vector Laboratories) followed by 5-bromo-4-chloro-3-indolylphosphate/nitroblue tetrazolium (Sigma) substrate. Spots were counted using a dissecting microscope.
|
|
|---|
![]() View larger version (60K): [in a new window] |
FIG. 2. Amplification of LouTat 1 and 117 VSG mRNAs from LT1:117 VSG double expressers. LT1:117 total RNA was isolated using the Ultraspec-II RNA isolation system. The T-lymphocyte-triggering factor LouTat 1 VSG, and 117 VSG genes were amplified using gene-specific primers. A reaction control was provided with the Access RT-PCR core kit (Promega, Madison, WI). Appropriate negative controls were also run (not shown), and trypanosomes expressing monotypic coats expressed only the relevant VSG gene transcripts (not shown).
|
![]() View larger version (15K): [in a new window] |
FIG. 3. LouTat 1 and LT1:117 trypanosomes exhibit similar infectivity and growth patterns. C57BL/6 wt (left) and C57BL/6 scid (right) mice were infected with 105 viable trypanosomes and the early parasitemia profiles monitored. The data presented are from individual mouse infections but are representative of parasitemia profiles for 10 mice infected with each strain. Parasitemia scores: 4 = >100 trypanosomes per 400x field; 1 = 1 to 5 trypanosomes per 10 400x microscope fields. Symbols: , LouTat 1; , LT1:117.
|
![]() View larger version (42K): [in a new window] |
FIG. 4. LouTat 1 VSG and 117 VSG are stably coexpressed for up to 1 week by LT1:117 VSG gene double expressers in the absence of immune selection. C57BL/6 scid mice were infected with 105 LouTat 1 or LT1:117 trypanosomes in the presence or absence of G418 drug selection. VSG expression was monitored on trypanosomes by immunofluorescence staining with LouTat 1 VSG- and 117 VSG-specific antibodies at days 7 and 14 postinfection.
|
![]() View larger version (54K): [in a new window] |
FIG. 5. LouTat 1 VSG and 117 VSG colocalize to the endoplasmic reticulum, flagellar pocket, and cell surface in LT1:117 VSG gene double expressers. G418-selected trypanosomes were fixed with 1% formaldehyde/0.05% glutaraldehyde and attached to slides by acetone/methanol fixation. Slides were stained with a mouse anti-LouTat 1 VSG monoclonal antibody and a rabbit anti-117 polyclonal serum. Positive cells were detected using Alexa 633-conjugated anti-mouse IgM (red) and Alexa 488-conjugated anti-rabbit IgM (green) and viewed by fluorescent microscopy. Immunostaining: (A) mouse anti-LouTat 1 VSG; (B) rabbit anti-117 VSG; (C) merged image; (D) differential interference contrast with DAPI counterstain. Control stains demonstrated that these antibodies do not cross-react with the heterologous VSG in this assay. Images were pseudocolored and merged using OpenLabs 3.0 software (Improvision, Inc., Lexington, MA).
|
![]() View larger version (34K): [in a new window] |
FIG. 6. Similar amounts of LouTat 1 VSG and 117 VSG are present in LT1:117 VSG double-expresser trypanosomes. Trypanosomes were metabolically labeled with [35S]methionine and [35S]cysteine in Met/Cys-depleted medium for 4 h. Cells were lysed, and the lysates were incubated with rabbit anti-LouTat 1 VSG or anti-117 VSG antibodies coupled to Sepharose A beads. Equivalent amounts of immunoprecipitated material were separated by SDS-PAGE and the bands detected by autoradiography. Band density was measured using GeneTools imaging software (Hitachi Genetic Systems; Hitachi Software Engineering Co., Ltd.). Scan pixel densities for precipitated LouTat 1 and 117 VSGs in autoradiograms were 1,422,050 and 1,036,078, respectively.
|
Immune response to the mosaic VSG coat. We hypothesized that disruption of the homogeneous array of VSG epitopes present in the surface coat of trypanosomes by insertion of an additional VSG protein would negatively impact the ability of B cells to recognize and become activated by VSG epitopes within the surface coat. To test this hypothesis, we infected athymic C57BL/6 nu/nu mice with 105 LouTat 1 or LT1:117 trypanosomes. Both T-independent and T-dependent VSG-specific B-cell responses to VSG normally occur during infection of wt mice, but the T-dependent B-cell responses (including isotype switching) appear after the T-independent response has already cleared trypanosomes from the circulation (36). Thus, the use of athymic nude mice in the present study ensured that the B-cell responses detected were strictly T independent and represented the early B-cell response during infection. We examined B-cell activation during the first 5 days of infection by VSG-specific ELISA to measure antigen-specific antibody present in sera and by ELISPOT to enumerate splenic B cells secreting antibody. The focus on the first 5 days was reinforced by earlier data showing that the B-cell response during this period is normally sufficient to provide variant-specific immunity; the importance of T-independent VSG-specific IgM responses in controlling the first wave of parasitemia has been demonstrated (27, 28, 33). Also, we were concerned that a loss of 117 VSG gene and protein expression in even a subset of trypanosomes after 5 days would skew immunological results at later time points of infection in a manner that could not be controlled for. Therefore, we examined only animals infected with VSG double expressers during the 5-day period in which there was no demonstrable loss of ectopic VSG gene and protein expression in the organisms.
Infected C57BL/6 nu/nu mice were sacrificed on specific days postinfection, serum was isolated from whole blood and pooled, and relative antibody titers were measured by LouTat 1 VSG- and 117 VSG-specific ELISAs. Antibodies against both coat VSG constituents were depressed in animals infected with the VSG double expresser LT1:117; this was in contrast to the homogeneous single-VSG-expressing parental organism, which induced rapid and high levels of VSG-specific antibody (Fig. 7). Similarly, VSG-specific ELISPOT assays using splenocytes from trypanosome-infected C57BL/6 nu/nu mice clearly demonstrated that fewer B cells were stimulated to produce VSG-specific antibodies against coat determinants during LT1:117 infection than during LouTat 1 infection (Fig. 7). It is noteworthy that mice infected with the monotypic LouTat 1 variant generate cross-reactive antibodies against the 117 VSG molecule; this may be due to minor sub-sequence identity between the two VSGs, which are closely related with regard to type and class (see Materials and Methods). However, even this cross-reactive antibody response was depressed when animals were infected with the mosaic coat double expressers. This finding was also apparent in the B-cell ELISPOT data.
![]() View larger version (20K): [in a new window] |
FIG. 7. VSG-specific B-cell responses are depressed during infection with VSG double expressers relative to those for infection with the wt strain. C57BL/6 nu/nu mice were infected with 105 trypanosomes expressing either a homogeneous LouTat 1 VSG coat or the mosaic LT1:117 VSG coat. (Top) Serum was collected on the days indicated and analyzed by VSG-specific ELISAs using LouTat 1 VSG (left) or 117 VSG (right) as the capture molecule. Data are presented as relative change in optical density (OD) ± standard deviation from five separate experiments over an 8-month period. (Bottom) ELISPOT assays were performed with spleen cells from infected mice. Data are presented as mean number of antibody-forming cells (AFC)/105 spleen cells from a single experiment. Symbols: , LouTat 1-infected mice; , LT1:117-infected mice; , uninfected mice.
|
|
|
|---|
Previous studies by other laboratories have shown that trypanosomes alter their surface coat during antigenic variation in vivo via establishment of a transient intermediate state in which two VSGs are expressed on the cell surface (1, 4, 19). Munoz-Jordan et al. demonstrated that there are no physiological or molecular barriers to constitutive, stable expression of two VSG species within the surface coat (30). Their study indicated that African trypanosomes were able to stably express two VSGs on the cell surface in a system in which an exogenous VSG gene was inserted into the active telomeric VSG gene expression site of the targeted parasite and was cotranscribed as part of site-specific polycistronic transcription, resulting in expression of both the endogenous and exogenous VSGs on the cell surface. Population doubling times and infectivity were similar for the parental single VSG expresser and the transformed VSG double-expresser strain, demonstrating for the first time that there were no intrinsic barriers to long-term expression of a mosaic VSG coat. However, no study detailing the effects of such a coat on the host immune response had been undertaken.
In the present study, we describe the construction of VSG double-expresser trypanosomes in which the VSG117 gene was expressed ectopically from the rRNA locus of T. b. rhodesiense LouTat 1. This model system and strategy were chosen for several reasons, the first and most prominent of which was that previous studies in this laboratory have extensively characterized the host immune response to the LouTat 1 variant in terms of both adaptive and innate immunity in several host genetic backgrounds (14-16, 21, 22, 32, 33, 35, 36, 45, 46). Relatively resistant mice (C57BL/6) infected with LouTat 1 trypanosomes live approximately 50 days postinfection and produce significant VSG-specific antibody responses during infection. Thus, we were extremely familiar with many aspects of the host-parasite interaction, and this disease model allowed us to study critically the host antibody response over time. Second, the VSG double expressers previously described by another lab were constructed in highly virulent strains of T. b. brucei that typically cause death of mice within 3 days, rendering such organisms unsuitable for most immunological studies (30). Third, ribosomal targeting of the 117 VSG gene was chosen because the pXS5neo117 vector was readily available and had been utilized in prior studies in T. b. brucei in which an exogenous VSG gene was expressed at high levels (5, 7). Fourth, VSG in the native telomeric expression site is transcribed by RNA polymerase I in vivo as part of a long polycistronic transcript; thus, one may predict that the same high level of transcription could be achieved by targeting the exogenous VSG gene to the ribosomal locus, where it would also be transcribed by RNA polymerase I behind the rRNA promoter (20, 24). We demonstrate here that the endogenous LouTat 1 VSG and the exogenous 117 VSG were produced in readily detectable quantities regardless of transcriptional loci and that the two VSG molecules trafficked to the cell surface in equivalent amounts to produce a mosaic coat. While we cannot prove that equimolar amounts of the two VSGs are present in the surface coat of the double expressers, it is clear that there is uniform distribution and colocalization of the two VSGs within the surface coat. Thus, the double-expresser surface coat is one in which the normally homogeneous LouTat 1 VSG coat has been disrupted by the presence of a different VSG molecule.
As in the earlier study of double expressers, introduction and expression of an exogenous VSG gene did not appear to alter the normal cell biology of the LouTat 1 parasite. Infectivity and the peak values observed in the first wave of parasitemia were similar for LT1:117 and the wt parental strain, although the double expressers initially grew to higher levels in infected mice on day 3, before the peak parasitemia occurred. Furthermore, subsequent waves of parasitemia in immunocompetent mice infected with the double expressers appeared to be less well-controlled than those with the wt trypanosomes. However, expression of an initial heterogeneous mosaic coat by the infecting parasite did not affect the overall survival time of the infected host. It is noteworthy that, given the reduced ability of host B cells to produce VSG-specific IgM antibodies against coat determinants of LT1:117, the double expresser initially grew to higher levels than LouTat 1. However, the LT:117 and LouTat 1 trypanosomes were eliminated with essentially the same kinetics following the first peak of parasitemia. One explanation for this observation may be that low levels of antibody generated by days 3 to 5 of infection against the 117 VSG component of the surface coat (Fig. 7) may have been sufficient to affect clearance. An alternative suggestion is that there were sufficient but small numbers of VSG double-expresser trypanosomes that displayed a mosaic coat with a greater degree of 117 VSG than LouTat 1 VSG expression (e.g., essentially resembling parasites completing the switch process); this may have provided sufficient cross-linking of the B-cell receptor to trigger a response. It is also possible that an attribute of the trypanosome, rather than a result of the host-parasite interaction, may be responsible. For example, recent studies have demonstrated that parasitemia is reduced significantly after the first peak during infection of IgM/ mice (Sandor et al., unpublished data). This may reflect an innate ability of the organism to control its population size, perhaps by a mechanism similar to quorum sensing in prokaryotes, in the interest of sustaining a long-term infection to increase its chances of transmission (34, 44). It has also been suggested that parasitemia may be partially controlled by differentiation of dividing long-slender trypanosomes to senescent short-stumpy forms in preparation for transmission to the insect vector and that normal cell death of these nondividing parasites contributes to the apparent clearance of parasitemia (reviewed in reference 8). It is possible that LT1:117 double expressers differentiate to the short-stumpy morphology with different kinetics than the parental LouTat strain, although there is presently no evidence supporting this speculation. These ideas are clearly open for further investigation.
The technical approach taken in this study was not without drawbacks. As noted above, expression of the 117 VSG gene in double expressers was significantly down-regulated or lost during extended infection, despite drug selection of the organisms prior to each experimental infection (it is perhaps not unexpected that an ectopic gene could cease expression or be lost in the absence of continual drug selection). This phenomenon did not appear to affect the stability of surface expression of the ectopically expressed VSG during the first 5 to 7 days of an experimental infection (Fig. 4), but this observation was the basis for our decision to limit analyses of B-cell responses to the first 5 days of infection.
Originally, trypanosomes were cloned by limiting dilution and by visual confirmation to establish a clonal infection from a single double-expresser trypanosome, from which frozen stocks were prepared in order to establish future infections. Each experimental infection was preceded by expansion of a frozen stabilate in G418-treated C57BL/6 scid mice; thus, all experimental infectious populations were no more than a few passages from the original drug-selected transformants. However, frozen stocks that were stored at 80°C for extended periods also lost expression of the 117 VSG gene. Perhaps a very small percentage of LT1:117 trypanosomes down-regulate or lose expression of 117 VSG during infection, and these cells are better able to withstand storage for long periods, or possess an imperceptible but significant selective advantage over true double expressers under G418 selection when the stabilates are revived from frozen storage. It is unknown whether ribosomal targeting of the exogenous 117 VSG gene influences this phenomenon, but anecdotal evidence from several labs suggests this is true. As a result, work is ongoing in our lab to express the 117 VSG from the tubulin locus using pXS5neo117 in which the ribosomal targeting sequence has been removed and the plasmid linearized for insertion into the
ß-tubulin intergenic sequence. However, it is likely that the surest way to ensure stable insertion and transcription of the ectopic VSG gene is to directly insert the 117 VSG gene into the active LouTat 1 VSG expression site, in a manner similar to that employed by Munoz-Jordan et al. (30). Work is currently under way in our laboratory to establish such a system, although there is no VSG pseudogene upstream from the LouTat 1 VSG gene in the expression site to serve as a proper targeting site for gene insertion (Inverso et al., submitted for publication).
The data presented here indicate that the level of 117 VSG expressed on the surface of LT1:117 is sufficient to disrupt the overall surface architecture of the LouTat 1 surface coat, resulting in the comparative inability of T-independent B cells to produce an early, robust VSG-specific antibody response against surface determinants. It is apparent from immunoprecipitation analyses that relatively smaller quantities of total 117 VSG are being produced in this system (Fig. 6) but that both LouTat and 117 VSGs are being successfully expressed on the cell surface (Fig. 5). These data indicate that disruption of the homotypic LouTat surface coat with 117 VSG, even if these coat constituents are not present in equal proportions, is sufficient to modulate VAT-specific host B-cell responses to the parasite (Fig. 7). We believe we have maintained the gross surface architecture (i.e., changed only the VSG epitopes presented and not the VSG homodimer conformation within the coat architecture), since the 117 and LouTat 1 VSGs are predicted to have very similar three-dimensional structures, as both are class 1, type A, with respect to their C-terminal and N-terminal domain configurations, respectively (11, 37). We predicted that the 117 and LouTat 1 VSGs should integrate readily in the surface coat, and our data support that prediction, since the two VSGs were uniformly distributed and no patching or capping was evident. Therefore, we propose that disruption of the homogeneous array of identical epitopes that occurs following insertion of nascent VSG molecules into the coat during antigenic variation may provide the parasite a degree of antigenic stealth until the new coat reaches some prescribed degree of homogeneity that permits T-independent B cells to recognize and be activated by a surface array of identical epitopes. This constitutes a previously unrecognized mechanism of immune response evasion by the African trypanosomes.
We thank G. A. M. Cross of the Rockefeller University for generous advice and helpful insights throughout this project. We are also grateful to James D. Bangs of the University of WisconsinMadison for assistance in this study.
|
|
|---|
dependent. J. Immunol. 161:6775-6783.
-dependent nitric oxide production is not linked to resistance in experimental African trypanosomiasis. Cell. Immunol. 192:24-32.[CrossRef][Medline]
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»